Category Archives: Business and Investments

Latest From Business and Investments

Answering the Call for Cures in Michigan

21st-Century-Cures--Free

This week, the Kalamazoo Gazette published an op-ed on how we can accelerate the discovery, development and delivery of treatments and cures for patients written by Stephen Rapundalo, President and CEO of MichBio, and BIO’s Jim Greenwood. The op-ed highlights the focus of roundtable discussions being held across the country as part of the 21st Century Cures Initiative. The U.S. House of Representatives’ Energy and Commerce Committee launched the initiative – led by Chairman Fred Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Biotech CEOs Talk JOBS Act and IPO Experiences at 2014 BIO Investor Forum

Biotech IPOs Infographic

The JOBS Act has contributed to a dramatic acceleration in new biotech IPOs since its passage, with nearly a tripling in the rate of companies going public in the industry. By changing how entrepreneurs can access and communicate with investors earlier in the process, the JOBS Act has fundamentally shifted how CEOs of discovery-driven companies must spend their time dealing with internal versus external priorities. Yesterday at the 2014 BIO Investor Forum, a panel of Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Investor Forum Company Snapshot: Syntrix Biosystems

SyntrixBioLogo_3D

1.     What is your company’s lead product or technology? Omnitram (O-desmethyltramadol) is a novel  oral analgesic developed by Syntrix that alleviates pain via a dual mechanism involving mu-opioid receptor activation and inhibition of the reuptake of norepinephrine.  Omnitram is in clinical development and has just completed a Phase 1b double-blind, placebo-controlled clinical trial (N=40) in experimental pain. 2.     What sets your company apart from competitors? Omnitram is a proprietary solution for pain relief that is Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Urges Comprehensive Tax Reform

72263479

Earlier this week, the Treasury Department issued a notice of its intent to propose rules to limit corporate inversions. In response, we are urging Congress and the Administration to reform the corporate tax system in order to maintain America’s global competitiveness, sustain and create American jobs, and encourage investments in the United States. The U.S. has one of the highest effective corporate tax rates in the world. Current U.S. corporate tax laws, including the lack Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Members of Congress Agree: Reg A+ Rules Need National Standard

Biotech IPOs Infographic

We’ve written before about the importance of implementing Title IV of the JOBS Act (commonly referred to as the “Reg A+” provision) in a way that will best encourage biotech capital formation. BIO President and CEO Jim Greenwood also discussed the issue in an op-ed at Forbes last week. At issue is whether the SEC will set a national standard for the review of Reg A+ offerings or instead subject companies to the labyrinth that Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,